Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 22 May 2019, that Mike McGoun, a Non-Executive Director of the Company, sold 30,000 ordinary shares of 10p each in the Company ("Ordinary Shares") on 21 May 2019 at a price of 347.55 pence per Ordinary Share.
Following the transaction, Mike now has a total interest in 6,786 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Non Executive Director
Initial notification /Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit instem.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Phil Reason, chief executive of Instem Plc (LON:INS), caught up with Proactive to discuss their first-half 2018 trading update.
He says trading's been in line with expectations with the standout performer being their SEND platform where the value of contracts won so far this year has...